Interleukin-1 Modulation in Osteoarthritis Therapy

Osteoarthritis is increasingly recognised as a disorder with both mechanical and inflammatory components, in which interleukin-1 (IL-1) plays a central role by driving cartilage degradation, synovial inflammation and subchondral bone changes. Modulating IL-1 activity has emerged as a promising strategy to both relieve symptoms and alter disease progression. Approaches range from competitive receptor antagonists and monoclonal antibodies to engineered protein fragments and controlled-release systems. By blocking the interaction of IL-1α and IL-1β with their receptor (IL-1R1), these therapies aim to reduce proinflammatory cascades, inhibit matrix-degrading enzymes and promote tissue repair. Recent advances in molecular design, biomaterial delivery and clinical evaluation are beginning to clarify the therapeutic potential of IL-1 modulation in diverse patient populations and disease stages, with a view to more personalised, disease-modifying interventions.

Research from Nature Portfolio

Researchers have applied computational modelling and protein engineering to develop a truncated form of the IL-1 receptor antagonist (IL-1RA) that retains high affinity for IL-1R1 despite a significantly reduced size. In silico predictions identified non-binding regions of the native antagonist, leading to a 41-amino-acid fragment with enhanced receptor interaction energy and improved stability in molecular dynamics simulations. This engineered ligand displayed lower free binding energy than the full-length protein, suggesting greater antagonistic potency. The study illustrates how structure-based design can yield next-generation IL-1 blockers that may be more amenable to peripheral administration and tissue penetration, setting the stage for preclinical validation of small-format biologics in osteoarthritis.

Interleukin-1 Modulation in Osteoarthritis Therapy publication trend

The graph below shows the total number of articles in interleukin-1 modulation in osteoarthritis therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Interleukin-1 (IL-1): A proinflammatory cytokine family including IL-1α and IL-1β that promotes cartilage breakdown and joint inflammation.

IL-1 receptor antagonist (IL-1RA): An endogenous inhibitor that competes with IL-1α/β for binding to IL-1R1, preventing signal transduction.

Monoclonal antibody: A laboratory-derived immunoglobulin engineered to bind a specific antigen, such as IL-1 or its receptor.

Cytokine: A small secreted protein that regulates immune and inflammatory processes.

Sustained-release delivery: A formulation approach that allows gradual release of a therapeutic agent over time to maintain effective local concentrations.

References

1. Efficacy and safety of anti-interleukin-1 therapeutics in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Journal of Orthopaedic Surgery and Research (2023).
2. Efficacy of Anti-Interleukin-1 Therapeutics in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials from the Years 2000 to 2023. Journal of Clinical Medicine (2024).
3. Optimization of IL-1RA structure to achieve a smaller protein with a higher affinity to its receptor. Scientific Reports (2022).